SCHEMBL19258711

SCHEMBL19258711

O=C(O)CC(CC(=O)O)(C(=O)O)C(C(CC(=O)O)(CC(=O)O)C(=O)O)C(CC(=O)O)(CC(=O)O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 2/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
ACLY P53396 3/20 0.41
CPT2 P23786 2/20 0.41
HMGCR P04035 1/20 0.39
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
ADRA1A P35348 1/20 0.39
TDP1 Q9NUW8 2/20 0.35
KDM4E B2RXH2 1/20 0.33
FFAR1 O14842 1/20 0.33
HSPD1 P10809 1/20 0.31
BLM P54132 1/20 0.31
HSPE1 P61604 1/20 0.31
SLC22A6 Q4U2R8 1/20 0.30
LDHA P00338 1/20 0.30
SRR Q9GZT4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12524010 0.78 ACLY (0.43) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL18798915 0.78 ACLY (0.43) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL23772237 0.78 CYP2C19 (0.46) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL12528005 0.76 ACLY (0.58) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL12458905 0.72 ACLY (0.39) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL18798472 0.72 ACLY (0.39) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL18798923 0.71 ACLY (0.38) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL12458904 0.71 ACLY (0.38) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL22421672 0.69 CYP2C19 (0.43) ALDH1A1CYP2C19HIF1ACYP2D6TSHR
SCHEMBL2446996 0.65 ALDH1A1 (0.53) ALDH1A1CYP2C19HIF1ACYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170232013-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170232013-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES CS, ACLY, CA5A ALDH1A1 1294/4885CYP2C19 878/4885HIF1A 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.